COMPANY PROFILE // THE 014 REPORT
Kyverna Therapeutics, Inc.
KYTX (Nasdaq)
Assembled from 4 government sources in 0.4 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber4 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-05-18: a pattern of leadership change.
✓ SEC filings✓ State registrationpossible match✓ Lobbying registrationpossible match✗ LEI✗ SAM registration✗ IRS return✗ Website
No LEI, no SAM registration, no IRS return, no website on record.
Kyverna Therapeutics, Inc. is an SEC-registered operating company in biological products, (no diagnostic substances), incorporated in DE, based in Emeryville, CA; listed as KYTX (Nasdaq).[source] It has filed 69 documents with the SEC in the last 12 months; the latest is a SCHEDULE 13G/A, filed 2026-11-16.[source] 2 lobbying disclosure filings name a client with this company's exact name (possible match).[source] Its largest institutional holders on 13F filings are GordonMD Global Investments LP, GILEAD SCIENCES, INC., BlackRock, Inc. (as of 2026-06-30).[source] Seraphix flags 1 item from these records: 4 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-05-18.[source]
- red0
- amber1
- info0
- GordonMD Global Investments LP$37.8M
- GILEAD SCIENCES, INC.$36.8M
- BlackRock, Inc.$27.9M
- Bain Capital Life Sciences Investors, LLC$25.7M
- AIGH Capital Management LLC$24.9M
- DEERFIELD MANAGEMENT COMPANY, L.P.$17.8M
- VANGUARD CAPITAL MANAGEMENT LLC$16.9M
- GEODE CAPITAL MANAGEMENT, LLC$9.4M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Biddle Warner Weston · Chief Executive Officer (Director,Officer) · latest Form 4 2026-03-17 · filing · LinkedIn search
- GEHCHAN NAJI · See Remarks (Officer) · latest Form 4 2026-03-17 · filing · LinkedIn search
- GRASSO MARC · Chief Financial Officer (Officer) · latest Form 4 2026-03-17 · filing · LinkedIn search
- Jones Ryan Alexander · Chief Financial Officer (Officer) · latest Form 4 2025-04-15 · filing · LinkedIn search
- Pujols Mayobanex · Chief Technology Officer (Officer) · latest Form 3 2026-02-11 · filing · LinkedIn search
- Shaw Christi · Executive Chairperson (Director,Officer) · latest Form 4 2026-01-14 · filing · LinkedIn search
- Walker Karen Marie · Chief Technology Officer (Officer) · latest Form 4 2025-12-17 · filing · LinkedIn search
- Aktar Mert · Director · latest Form 4 2025-06-02 · filing · LinkedIn search
- CLARK IAN T · Director · latest Form 4 2025-06-02 · filing · LinkedIn search
- Cohen Fred E · Director,10% owner · latest Form 4 2025-06-02 · filing · LinkedIn search
- Emany Sravan Kumar · Director · latest Form 4 2026-02-26 · filing · LinkedIn search
- Miller Andrew Craig · Director · latest Form 3 2026-03-04 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- Paul Hastings LLP · Exhibit 5.1 legal opinion, S-8 filed 2026-03-26
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 25 CLEAR, 1 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001994702 | source |
| EIN | 83-1365441 | source |
| NY DOS ID | 7365306 | record |
| Connecticut business ID | 3508477 | record |
| LDA clientpossible match | 72192 | record |
| LDA clientpossible match | 69525 | record |
| Business address (SEC) | 5980 HORTON STREET, SUITE 200, EMERYVILLE, CA | source |
Does not exist in the records we hold: LEI, UEI, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 129 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 174 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2836 (biological products, (no diagnostic substances)): 183 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- AMGEN INC · 123 SEC filings in 12 months · 1 flag · $507.4M federal (possible match)
- Vir Biotechnology, Inc. · 117 SEC filings in 12 months · 1 flag · $65.9M federal (possible match)
- Vericel Corp · 109 SEC filings in 12 months · 1 flag · $37.3M federal (possible match)
- Coherus Oncology, Inc. · 53 SEC filings in 12 months · 3 flags · $11.8M federal (possible match)
- BIO-TECHNE Corp · 77 SEC filings in 12 months · 1 flag · $6.6M federal (possible match)
- Twist Bioscience Corp · 337 SEC filings in 12 months · 2 flags · $5.9M federal (possible match)
- Adaptive Biotechnologies Corp · 185 SEC filings in 12 months · 1 flag · $1.9M federal (possible match)
- AGENUS INC · 82 SEC filings in 12 months · 3 flags · $613K federal (possible match)
- REPLIGEN CORP · 89 SEC filings in 12 months · 1 flag · $457K federal (possible match)
- Revolution Medicines, Inc. · 171 SEC filings in 12 months · 2 flags · $15K federal (possible match)
- RECURSION PHARMACEUTICALS, INC. · 174 SEC filings in 12 months · 1 flag
- GILEAD SCIENCES, INC. · 173 SEC filings in 12 months
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- Alto Neuroscience, Inc. · Miller Andrew Craig
- Assertio Holdings, Inc. · Sravan Emany
- BIOMARIN PHARMACEUTICAL INC · Ian Clark
- Beam Therapeutics Inc. · Christi Shaw
- Beam Therapeutics Inc. · Sravan Emany
- CareDx, Inc. · Fred E. Cohen, M.D., D.Phil.
- Corvus Pharmaceuticals, Inc. · Ian Clark
- Electra Therapeutics, Inc. · Westlake BioPartners Fund I, L.P.
- Guardant Health, Inc. · Ian Clark
- IRONWOOD PHARMACEUTICALS INC · Martini Gregory S.
- Intellia Therapeutics, Inc. · Fred E. Cohen, M.D., D.Phil.
- Latigo Biotherapeutics, Inc. · SEIDENBERG BETH C
- Latigo Biotherapeutics, Inc. · Westlake BioPartners Fund I, L.P.
- Olema Oncology, Inc. · Ian Clark
- Sagimet Biosciences Inc. · SEIDENBERG BETH C
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-16 name change Name changed from Kyverna Therapeutics, Inc. · SEC EDGAR
- 2026-11-12 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-12 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-09-24 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-08-11 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-11 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-07-27 filing 8-K items 1.01,7.01,9.01 · SEC EDGAR
- 2026-07-09 filing 8-K items 1.01,9.01 · SEC EDGAR
- 2026-06-02 filing 8-K items 5.07,9.01 · SEC EDGAR
- 2026-05-18 officer change 8-K items 5.02,8.01,9.01 · SEC EDGAR
- 2026-05-12 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-12 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-05-04 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-04-22 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-04-22 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-04-20 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-04-17 filing 144 · SEC EDGAR
- 2026-04-14 filing 144 · SEC EDGAR
- 2026-04-13 filing ARS · SEC EDGAR
- 2026-04-13 filing DEFA14A · SEC EDGAR
- 2026-04-13 filing Proxy statement · SEC EDGAR
- 2026-04-07 filing 144 · SEC EDGAR
- 2026-04-02 filing EFFECT · SEC EDGAR
- 2026-04-02 filing 424B5 · SEC EDGAR
- 2026-03-31 filing 144 · SEC EDGAR
- 2026-03-31 filing CORRESP · SEC EDGAR
- 2026-03-30 filing UPLOAD · SEC EDGAR
- 2026-03-26 filing S-8 · SEC EDGAR
- 2026-03-26 filing S-3 · SEC EDGAR
- 2026-03-26 filing Annual report (10-K) · SEC EDGAR
94 earlier entries
- 2026-03-26 filing 8-K items 2.02,9.01
- 2026-03-17 insider First Form 3/4/5 on record for GEHCHAN NAJI (See Remarks)
- 2026-03-04 insider First Form 3/4/5 on record for Miller Andrew Craig (Director)
- 2026-02-26 insider First Form 3/4/5 on record for Emany Sravan Kumar (Director)
- 2026-02-24 officer change 8-K items 5.02,8.01,9.01
- 2026-02-11 insider First Form 3/4/5 on record for Pujols Mayobanex (Chief Technology Officer)
- 2026-02-03 officer change 8-K items 5.02,8.01,9.01
- 2026-01-12 officer change 8-K items 2.02,5.02,9.01
- 2025-12-18 filing 8-K items 1.01,8.01,9.01
- 2025-12-18 filing 424B5
- 2025-12-17 filing FWP
- 2025-12-15 filing 424B5
- 2025-12-15 filing 144
- 2025-12-15 filing 8-K items 7.01,9.01
- 2025-12-15 filing 8-K items 7.01,9.01
- 2025-11-12 filing Quarterly report (10-Q)
- 2025-11-12 filing 8-K items 2.02,9.01
- 2025-11-03 filing 8-K items 1.01,2.03,7.01,9.01
- 2025-10-29 filing 8-K items 7.01,9.01
- 2025-10-29 filing 8-K items 7.01,9.01
- 2025-09-25 officer change 8-K items 5.02,9.01
- 2025-08-12 filing Quarterly report (10-Q)
- 2025-08-12 filing 8-K items 2.02,9.01
- 2025-07-01 insider First Form 3/4/5 on record for GRASSO MARC (Chief Financial Officer)
- 2025-06-30 officer change 8-K items 5.02,8.01,9.01
- 2025-06-03 filing 8-K items 5.07,9.01
- 2025-06-02 insider First Form 3/4/5 on record for Shaw Christi (Executive Chairperson)
- 2025-06-02 insider First Form 3/4/5 on record for Aktar Mert (Director)
- 2025-06-02 insider First Form 3/4/5 on record for CLARK IAN T (Director)
- 2025-06-02 insider First Form 3/4/5 on record for Cohen Fred E (Director,10% owner)
- 2025-06-02 insider First Form 3/4/5 on record for SEIDENBERG BETH C (Director)
- 2025-06-02 insider First Form 3/4/5 on record for SPIEGELMAN DANIEL K (Director)
- 2025-05-13 filing Quarterly report (10-Q)
- 2025-05-13 filing 8-K items 2.02,9.01
- 2025-04-15 filing EFFECT
- 2025-04-15 filing 424B5
- 2025-04-15 insider First Form 3/4/5 on record for Biddle Warner Weston (Chief Executive Officer)
- 2025-04-15 insider First Form 3/4/5 on record for Jones Ryan Alexander (Chief Financial Officer)
- 2025-04-15 insider First Form 3/4/5 on record for Walker Karen Marie (Chief Technology Officer)
- 2025-04-14 filing ARS
- 2025-04-14 filing DEFA14A
- 2025-04-14 filing Proxy statement
- 2025-04-11 filing CORRESP
- 2025-04-01 filing UPLOAD
- 2025-03-27 filing 8-K items 1.01,9.01
- 2025-03-27 filing S-8
- 2025-03-27 filing S-3
- 2025-03-27 filing Annual report (10-K)
- 2025-03-27 filing 8-K items 2.02,9.01
- 2025-01-21 filing 8-K items 8.01,9.01
- 2025-01-13 filing 8-K items 7.01,9.01
- 2024-11-26 filing S-8
- 2024-11-26 officer change 8-K items 5.02,9.01
- 2024-11-13 filing Quarterly report (10-Q)
- 2024-11-13 officer change 8-K items 2.02,5.02,9.01
- 2024-10-21 officer change 8-K items 5.02,8.01,9.01
- 2024-09-16 officer change 8-K items 5.02,8.01,9.01
- 2024-08-12 filing Quarterly report (10-Q)
- 2024-08-12 filing 8-K items 2.02,9.01
- 2024-07-15 filing 8-K items 7.01,8.01,9.01
- 2024-07-11 filing UPLOAD
- 2024-06-14 filing 8-K items 7.01,9.01
- 2024-05-14 filing Quarterly report (10-Q)
- 2024-05-14 filing 8-K items 2.02,9.01
- 2024-05-03 filing SC 13D
- 2024-03-26 filing Annual report (10-K)
- 2024-03-26 filing 8-K items 2.02,9.01
- 2024-02-13 filing SEC STAFF LETTER
- 2024-02-12 filing 8-K items 5.03,8.01,9.01
- 2024-02-08 filing S-8
- 2024-02-08 filing 424B4
- 2024-02-08 filing CERT
- 2024-02-07 filing EFFECT
- 2024-02-06 filing S-1/A
- 2024-02-05 filing CORRESP
- 2024-02-05 filing CORRESP
- 2024-02-05 filing 8-A12B
- 2024-02-01 filing S-1/A
- 2024-01-25 filing CORRESP
- 2024-01-16 filing CORRESP
- 2024-01-16 filing Registration (S-1)
- 2024-01-10 filing UPLOAD
- 2024-01-08 filing DRS/A
- 2024-01-05 filing DRSLTR
- 2023-12-28 filing UPLOAD
- 2023-12-15 filing SEC STAFF LETTER
- 2023-12-13 filing DRSLTR
- 2023-12-13 filing DRS/A
- 2023-11-21 filing UPLOAD
- 2023-11-09 filing DRSLTR
- 2023-11-09 filing DRS/A
- 2023-11-07 filing D
- 2023-11-01 filing UPLOAD
- 2023-10-05 filing DRS
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-12 (within 30 days) 10-Q filed
- 2026-11-12 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-09-24 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-11 (older) 10-Q filed
- 2026-08-11 (older) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-27 (older) 8-K filed: Item 1.01 material agreement; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-07-10 (older) Form 5500 received for plan year ending 2025-12-31 (plan no. 501)
- 2026-07-09 (older) 8-K filed: Item 1.01 material agreement; Item 9.01 exhibits
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-22; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:KYTX The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
8 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1994702 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | KYTX / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 831365441 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001994702 | SEC EDGAR / IRS |
| CUSIP | 501976104 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001994702 | SEC EDGAR |
possible match: matched by name only, not merged (5)
Identifiers carried by records that share the company's exact name. Not merged into the identity above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| LDA client id | 69525 (KYVERNA THERAPEUTICS, INC. (lobbying via AKIN GUMP STRAUSS HAUER & FELD)) | name-exact:legal-name: same registered legal name as 'Kyverna Therapeutics, Inc.' | Lobbying Disclosure Act (LDA) |
| LDA client id | 72192 (KYVERNA THERAPEUTICS, INC. (lobbying via BROWNSTEIN HYATT FARBER SCHRECK, LLP)) | name-exact:legal-name: same registered legal name as 'Kyverna Therapeutics, Inc.' | Lobbying Disclosure Act (LDA) |
| EPA FRS id | 110071135246 (KYVERNA THERAPEUTICS) | name-exact: exact name match to 'Kyverna Therapeutics, Inc.' (no other entity shares the name) | EPA ECHO facilities |
| EPA FRS id | 110070900952 (KYVERNA THERAPEUTICS INC) | name-exact:legal-name: same registered legal name as 'Kyverna Therapeutics, Inc.' | EPA ECHO facilities |
| EPA FRS id | 110070900491 (KYVERNA THERAPEUTICS, INC) | name-exact:legal-name: same registered legal name as 'Kyverna Therapeutics, Inc.' | EPA ECHO facilities |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Net income (loss) (fiscal year ended 2025-12-31) | -$161,307,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-22 00:17 UTC | Report an error |
| Total assets (at 2025-12-31) | $293,826,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-22 00:17 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $232,276,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-22 00:17 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $124,093,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-22 00:17 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 00:17 UTC | Report an error |
| SIC industry | 2836 Biological Products, (No Diagnostic Substances) | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 00:17 UTC | Report an error |
| State of incorporation | DE | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 00:17 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 00:17 UTC | Report an error |
| Business address | 5980 HORTON STREET, SUITE 200, EMERYVILLE, CA | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 00:17 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 00:17 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$153,712,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-22 00:17 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $5,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-22 00:17 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $3,982,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-22 00:17 UTC | Report an error |
| Form D total offering amount (D filed 2023-11-07) | $151,999,981 | 2023-11-07 | D | as filed | 2026-11-22 00:17 UTC | Report an error |
| Form D total amount sold (D filed 2023-11-07) | $151,999,981 | 2023-11-07 | D | as filed | 2026-11-22 00:17 UTC | Report an error |
| Form D industry group | Biotechnology | 2023-11-07 | D | as filed | 2026-11-22 00:17 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2023-11-07 | D | as filed | 2026-11-22 00:17 UTC | Report an error |
| Form D date of first sale | 2021-11-09 | 2023-11-07 | D | as filed | 2026-11-22 00:17 UTC | Report an error |
| Plan (welfare, plan no. 501) | THE KYVERNA THERAPEUTICS, INC. EMPLOYEE BENEFITS PLAN: 134 participants | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-22 00:17 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-12 · accession 0001193125-26-457043
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Net income (loss) | -$41,941,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-12 | 0001193125-26-457043 | 2026-11-22 00:17 UTC | Report an error |
| Interest expense | $728,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-12 | 0001193125-26-457043 | 2026-11-22 00:17 UTC | Report an error |
| Cash and cash equivalents | $31,818,000 | at 2026-09-30 | 10-Q | 2026-11-12 | 0001193125-26-457043 | 2026-11-22 00:17 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-12 Filing 10-Q filed
- 2026-11-12 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-09-24 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-11 Filing 10-Q filed
- 2026-08-11 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-27 Filing 8-K filed: Item 1.01 material agreement; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-07-10 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 501)
- 2026-07-09 Filing 8-K filed: Item 1.01 material agreement; Item 9.01 exhibits
- 2026-06-24 Record earliest certified decision date in the file
- 2026-06-24 Record latest certified decision date in the file
- 2026-06-02 Filing 8-K filed: Item 5.07 shareholder vote; Item 9.01 exhibits
- 2026-05-18 Filing 8-K filed: Item 5.02 officer or director change; Item 8.01 other event; Item 9.01 exhibits
- 2026-05-12 Filing 10-Q filed
- 2026-05-12 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-05-04 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-04-22 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-04-22 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-04-20 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-04-13 Filing ARS filed
- 2026-04-13 Filing DEFA14A filed
- 2026-04-13 Filing DEF 14A filed
- 2026-04-02 Filing EFFECT filed
- 2026-04-02 Filing 424B5 filed
- 2026-03-31 Filing CORRESP filed
- 2026-03-30 Filing UPLOAD filed
4 earlier entries
- 2026-03-26 Filing S-8 filed
- 2026-03-26 Filing S-3 filed
- 2026-03-26 Filing 10-K filed
- 2024-10-01 Record plan effective date: THE KYVERNA THERAPEUTICS, INC. EMPLOYEE BENEFITS PLAN
8-K item text, as filed (excerpts)
- 2026-11-12 8-K Item 2.02, Results of Operations and Financial Condition
On November 12, 2026, Kyverna Therapeutics, Inc. (the “Company”) issued a press release providing a business update and reporting financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Current Report”). In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement… the 8-K · retrieved 2026-11-22 00:17 UTC - 2026-09-24 8-K Item 7.01, Regulation FD Disclosure
On September 24, 2026, Kyverna Therapeutics, Inc. (the “Company”) issued a press release announcing positive one-year data from its registrational trial, KYSA-8, of miv-cel (mivocabtagene autoleucel, KYV-101) in patients with stiff person syndrome, and positive longer-term follow-up data from the Phase 2 portion of its registrational trial, KYSA-6, of miv-cel in patients with generalized myasthenia gravis (gMG). The Company will host a conference call at 8:00 a.m. Eastern Time on September 24, 2026 to review the results. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in Item 7.01… the 8-K · retrieved 2026-11-22 00:17 UTC - 2026-08-11 8-K Item 2.02, Results of Operations and Financial Condition
On August 11, 2026, Kyverna Therapeutics, Inc. (the “Company”) issued a press release providing a business update and reporting financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Current Report”). In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other… the 8-K · retrieved 2026-11-22 00:17 UTC - 2026-07-27 8-K Item 1.01, Entry into a Material Definitive Agreement
As previously disclosed, on July 22, 2023, Kyverna Therapeutics, Inc. (the “Company”) entered into that certain Development and Manufacturing Services Agreement (as amended by Amendment #1 thereto on July 24, 2023, the “Prior Agreement”) with ElevateBio Basecamp, Inc. (“ElevateBio”), pursuant to which ElevateBio has provided the Company with cell manufacturing, release and testing services for the Company’s lead product candidate, mivocabtagene autoleucel, also known as “miv-cel” (the “Product”). On July 23, 2026, the Company and ElevateBio entered into a Clinical and Commercial Supply Agreement (the “Agreement”), which replaces the Prior Agreement in its entirety and pursuant to which… the 8-K · retrieved 2026-11-22 00:17 UTC - 2026-07-27 8-K Item 7.01, Regulation FD Disclosure
On July 27, 2026, the Company and ElevateBio issued a joint press release announcing the entry into the Agreement. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly… the 8-K · retrieved 2026-11-22 00:17 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · NAME ONLY6. Lobbying (LDA)
2 lobbying records carry this company's exact name, hiring 2 lobbying firms. These are possible matches until the accuracy score, so they are not counted in the headline.
possible match: matched by name only, not merged (2)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchKYVERNA THERAPEUTICS, INC. (lobbying via AKIN GUMP STRAUSS HAUER & FELD) · exact legal name · sx:lda:69525 Compare
- possible matchKYVERNA THERAPEUTICS, INC. (lobbying via BROWNSTEIN HYATT FARBER SCHRECK, LLP) · exact legal name · sx:lda:72192 Compare
POSSIBLE MATCHES · GROUPED BY SOURCE8. Enforcement by agency
EPA ECHO facilities (3)
possible match: matched by name only, not merged (3)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchKYVERNA THERAPEUTICS · exact name match to 'Kyverna Therapeutics, Inc.' (no other entity shares the name) · sx:epa:110071135246 Compare
- possible matchKYVERNA THERAPEUTICS INC · exact legal name · sx:epa:110070900952 Compare
- possible matchKYVERNA THERAPEUTICS, INC · exact legal name · sx:epa:110070900491 Compare
Each record's own page holds its date and the agency document. Matched by exact name only; none of these is counted in the headline.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | GordonMD Global Investments LP | $37,821,328 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:17 UTC | Report an error |
| 2 | GILEAD SCIENCES, INC. | $36,763,720 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:17 UTC | Report an error |
| 3 | BlackRock, Inc. | $27,931,130 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:17 UTC | Report an error |
| 4 | Bain Capital Life Sciences Investors, LLC | $25,705,350 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:17 UTC | Report an error |
| 5 | AIGH Capital Management LLC | $24,910,552 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:17 UTC | Report an error |
| 6 | DEERFIELD MANAGEMENT COMPANY, L.P. | $17,820,000 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:17 UTC | Report an error |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | $16,906,288 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:17 UTC | Report an error |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | $9,352,537 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:17 UTC | Report an error |
| 9 | Insight Holdings Group, LLC | $8,812,471 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:17 UTC | Report an error |
| 10 | STATE STREET CORP | $8,751,696 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:17 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
DOL H-1B (LCA) · WARN NOT HELD12. Labor
| Measure | Value | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|
| Employer name (as filed) | Kyverna Therapeutics, Inc. | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-22 00:17 UTC | Report an error |
| Certified LCAs | 1 | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-22 00:17 UTC | Report an error |
| Certified LCAs later withdrawn | 0 | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-22 00:17 UTC | Report an error |
| Total worker positions on certified LCAs | 1 | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-22 00:17 UTC | Report an error |
| Top job titles (title, LCA count) | Associate Director, Medical Engagement Operations (1) | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-22 00:17 UTC | Report an error |
| Wage offered, annualized (n, min, median, max) | median $206,000 (range $206,000-$206,000, 1 filings) | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-22 00:17 UTC | Report an error |
| Worksite states | CA | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-22 00:17 UTC | Report an error |
Unconfirmed: these labor figures (positions, worksite states, certified LCAs later withdrawn) are as read from DOL's quarterly LCA disclosure file. Seraphix's independent second check of them is not finished (11-19); they are shown as filed, not as verified.
WARN layoff notices: not held yet.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
3 state and city records carry this company's exact name, from 3 sources. Possible matches only.
Connecticut business registrations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchKYVERNA THERAPEUTICS, INC. · exact legal name · sx:ctsos:3508477 Compare
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchKyverna Therapeutics · exact name match to 'Kyverna Therapeutics, Inc.' (no other entity shares the name) · sx:ctgov:h2c587d91d066f6cc Compare
New York corporations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchKYVERNA THERAPEUTICS, INC. · exact legal name · sx:nydos:7365306 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1994702.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001994702. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.